Cost-Effectiveness Analysis of Posaconazole versus Liposomal Amphotericin B in the Treatment of Mucormycosis patients in Iran

• In: Poster Presentation
• At: Stockholm (Sweden) (2017)
• Type: Poster
• Poster code: P-D-022-Monday
• By: TAHERI, Saeed (Shahid Beheshti University of Medical Science, Dept. of pharmacoeconomics and Pharma Management, Tehran, Iran, Islamic Republic Of)
• Co-author(s): Saeed Taheri: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
  Leila Zarei: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
  Alireza Ghiamat: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
  Gholamhossein Mehralian: Dept. of Pharmacoeconomics and Pharma Management, Shahid Beheshti Univercity of Medical Science, Tehran, Iran, Islamic Republic Of
  
• Abstract:

  Backgrounds

  Mucormycosis is an invasive fungal infection with high mortality specially in decompensated diabetics and immunosuppressed patients. The Mucorales are inherently resistant to most widely used antifungal agents. Liposomal Amphotericin B (AmB) is an appropriate option for empirical therapy, whereas Posaconazole (PCZ), a new..

The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress. Please login